07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01,...
01:02 , Oct 1, 2015 |  BC Extra  |  Financial News

Woodford backs AMO in $25M series A round

AMO Pharma Ltd. (London, U.K.) raised $25 million in a series A round from Woodford Investment Management through its Woodford Patient Capital Trust plc (LSE:WPCT) fund. AMO plans to begin Phase I/IIa testing next year...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

TLN-4601: Phase II discontinued

Thallion discontinued an open-label Phase II trial after a planned interim analysis showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601 demonstrated stable disease after two 3-week cycles...
07:00 , Jun 15, 2009 |  BC Week In Review  |  Company News

Thallion cancer news

Thallion restructured and reduced headcount to 30-35 from 42-43 and has negotiated with its suppliers and other commitments to save cash. Thallion's lead compound is TLN-4601. The farnesylated dibenzodiazepinone is in Phase II testing...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Company News

Thallion cancer, infectious news

Thallion retained Desjardins Securities Inc. to explore strategic alternatives, including possible sale of the company. The move was triggered by an expression of interest by an undisclosed pharma. Thallion has three candidates in Phase II...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

TLN-4601: Phase II started

Thallion began an open-label, North American Phase II trial to evaluate 480 mg/m 2/day of intravenous TLN-4601 given for 2 weeks as part of a 21-day cycle in up to 40 patients as a second...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

TLN-4601: Phase II start

This quarter, Thallion plans to start an open-label, North American Phase II trial in up to 40 patients to evaluate 480mg/m 2/day of intravenous TLN-4601 given for 2 weeks on and 1 week off in...
07:00 , Apr 14, 2008 |  BC Week In Review  |  Clinical News

TLN-4601: Phase II start

This quarter, Thallion will begin a North American Phase II trial to evaluate IV TLN-4601 as monotherapy in 40 patients. Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec   Product: TLN-4601 (formerly ECO-4601)   Business: Cancer   Molecular...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Thallion preclinical data

In a rat brain tumor model, the average concentration of ECO-4601 in the tumor was 176 µg/g vs. 0.807 µg/g and 16.2 µg/mL in the brain and plasma, respectively. The farnesylated dibenzodiazepinone has completed Phase...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

ECO-4601: Additional Phase I/II data

Additional data from the open-label, Canadian Phase I/II ECO-4601-101 trial in 26 advanced cancer patients showed that IV ECO-4601 was safe and well tolerated at daily doses of up to 480 mg/m 2. Six of...